Abstract:Abstract Background: Skin toxicity, especially hand-foot syndrome (HFS), is one of the most common sorafenib-induced adverse events (AEs) in hepatocellular carcinoma (HCC) patients, leading to treatment interruption and failure. Mucocutaneous inflammation may cause HFS; therefore, we investigated whether celecoxib can alleviate HFS, improve patients' quality of life and increase survival when administered in conjunction with active therapy. Methods: Our randomized, open-label study prospectively enrolled 116 advanced HCC patients receiving sorafenib as targeted therapy from July 2015 to July 2016. All patients were randomly assigned (1:1) via a computer-generated sequence to receive sorafenib with or without celecoxib. Sorafenib-related AEs were recorded, Survival was compared between the two groups. Results: Compared to the Sorafenib group, the SoraCele group had lower incidence rates of ≥ grade 2 and grade 3 HFS (63.8% vs 29.3%, P < 0.001; 19.0% vs 3.4%, P = 0.008, respectively), hair loss, rash and abdominal pain. Kaplan-Meier analysis revealed a lower risk of ≥ grade 2 HFS (HR, 0.384; P = 0.002) and a lower dose reduction/interruption rate (46.6% to 15.5%, P < 0.001) in the SoraCele group. Cox proportional hazards regression analysis demonstrated that celecoxib was the only independent predictive factor of developing ≥ grade 2 HFS (HR, 0.414; P = 0.004). Longer progression-free survival (PFS) was also observed in the SoraCele group (P = 0.039), although overall survival was not prolonged (P = 0.305). Conclusions: Sorafenib+Celecoxib administration alleviated sorafenib-related skin toxicity. Longer PFS was achieved in clinical practice, although overall survival was not prolonged (ClinicalTrials.gov: NCT02961998). Keywords: hand-foot syndrome; celecoxib; sorafenib; hepatocellular carcinoma Citation Format: JIANCONG CHEN. Preventive effect of Celecoxib in Sorafenib-related hand-foot syndrome in hepatocellular carcinoma patients, a single-center, open-label, randomized, controlled clinical phase III trial [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 1131.

A Randomized Controlled Phase Ii Study Of The Prophylactic Effect Of Urea-Based Cream On The Hand-Foot Skin Reaction Associated With Sorafenib In Advanced Hepatocellular Carcinoma.

Randomized Controlled Trial of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients with Advanced Hepatocellular Carcinoma.

A Randomized, double-blind, placebo-controlled trial evaluating the effect of topical urea for secondary prophylaxis of hand foot skin reaction in renal cell cancer patients on sunitinib therapy

Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials

A multicenter, noncontrolled clinical study of sorafenib adjuvant therapy in advanced renal cell carcinoma.

Hand-foot-skin Reaction of Grade ≥ 2 Within Sixty Days As the Optimal Clinical Marker Best Help Predict Survival in Sorafenib Therapy for HCC

Abstract 1131: Preventive effect of Celecoxib in Sorafenib-related hand-foot syndrome in hepatocellular carcinoma patients, a single-center, open-label, randomized, controlled clinical phase III trial

Sorafenib in Treatment of Patients with Advanced Hepatocellular Carcinoma: a Systematic Review.

Sorafenib-associated Hand-Foot Skin Reaction: Practical Advice on Diagnosis, Mechanism, Prevention, and Management

A clinical scoring tool validated with machine learning for predicting severe hand–foot syndrome from sorafenib in hepatocellular carcinoma

Efficacy of Compound Traditional Chinese Medicine Oil in Alleviating Regorafenib-Induced Hand-Foot Skin Reaction.

S-Hbegf/sirt1 Circuit-Dictated Crosstalk Between Vascular Endothelial Cells and Keratinocytes Mediates Sorafenib-Induced Hand–foot Skin Reaction That Can Be Reversed by Nicotinamide

Early Sorafenib‐related Adverse Events Predict Therapy Response of TACE Plus Sorafenib: A Multicenter Clinical Study of 606 HCC Patients

Therapeutic Efficacy and Prognostic Factors of Sorafenib Treatment in Patients with Unresectable Primary Hepatocellular Carcinoma

Chemotherapy-induced hand foot syndrome: comparative efficacy and safety of pharmacological prophylaxis – systematic review and Bayesian network meta-analysis

Retrospective Analysis Of The Efficacy And Safety Of Sorafenib In Chinese Patients With Metastatic Renal Cell Carcinoma And Prognostic Factors Related To Overall Survival

Efficacy Of Sorafenib In Combination With Gemcitabine And Fluorouracil In Metastatic Renal-Cell Carcinoma: Preliminary Result Of A Multicenter Phase Ii Study.

Sorafenib Treatment of Asian Patients with Advanced Renal Cell Carcinoma (rcc) in Daily Practice: Subset Analysis of the Large Non-Interventional Predict Study

Efficacy of aluminum chloride in severe regorafenib-associated hand-foot skin reactions: a single-arm trial

Safety assessment of sorafenib in Chinese patients with unresectable hepatocellular carcinoma: subgroup analysis of the GIDEON study

Phase Ⅱ study of sorafenib as first line treatment in patients with metastatic renal cell carcinoma